Zelgen’s Jakitinib Phase III Study Meets Primary Endpoint for Myelofibrosis
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that its Phase III clinical study (ZGJAK016)...
Auto-immune
China NT Pharma Group Inks Licensing Deal for Orticumab in Asia
China-based China NT Pharma Group Company Ltd (HKG: 1011) has announced a licensing agreement with...
Changchun High & New Technology’s Jinnamab Approved for AOSD Clinical Study by US FDA
China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) has announced that it...
Ferring and I-Mab Expand Olamkicept Collaboration for Inflammatory Diseases
Swiss pharmaceutical company Ferring Pharmaceuticals has announced a strategic collaboration with China’s I-Mab Inc. (NASDAQ:...
Kangpu Biopharmaceuticals Begins Phase IIa Trial of KPG-818 for Systemic Lupus Erythematosus
Shanghai-based Kangpu Biopharmaceuticals, Ltd has announced the first patient dosing in a multicenter, randomized, double-blind,...
Huadong Medicine’s SaiYueXin Receives NMPA Approval for Pediatric Psoriasis Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA)...